2023年6月26日 · Phosphodiesterase inhibitors are class medications used in the management and treatment of chronic obstructive pulmonary disease (COPD), erectile dysfunction (ED), pulmonary arterial hypertension (PAH), benign prostatic hyperplasia (BPH), acute decompensated heart failure, psoriasis, psoriatic arthritis (PA), atopic dermatitis (AD), and neonatal...

Both PDE3A and PDE3B are expressed in vascular smooth muscle cells and are likely to modulate contraction. Their expression in vascular smooth muscle is altered under specific conditions such as elevated cAMP and hypoxia. [1] The PDE3 family in mammals consists of two members, PDE3A and PDE3B.

PDE3 inhibitors are a type of phosphodiesterase inhibitors. Inhibition of the PDE isoenzyme 3 leads to an increase of intracellular concentrations of the second messenger cyclic adenosine monophosphate (cAMP). cAMP mediates the phosphorylation of protein kinases, which in turn activates cardiac calcium channels.

PDE3 is sometimes referred to as cGMP-inhibited phosphodiesterase. Ibudilast, a neuroprotective and bronchodilator drug used mainly in the treatment of asthma and stroke.

2025年3月4日 · PDE3 inhibitors are indicated for the treatment of heart failure, coronary heart disease, and to prevent myocardial infarction. Finally, nonspecific phosphodiesterase inhibitors are used in the treatment of asthma and chronic obstructive pulmonary disease.

A PDE3 inhibitor is a type of drug that blocks the enzyme PDE3, which plays a role in breaking down cAMP. These inhibitors are used in clinical settings as non-glycoside cardiotonic drugs, particularly for cardiovascular conditions, by enhancing relaxation and potentially benefiting neonatal diseases like MAS.

2023年3月27日 · Cilostazol exerts its action by inhibiting phosphodiesterase activity and suppressing cAMP degradation. The inhibition of PDE3 allows for a rise in cAMP in platelets and blood vessels.

2008年12月8日 · PDEs modulate crosstalk and feedback signaling through cAMP, cGMP, and their associated kinases. PDE3, 4, and 5 are phosphorylated and activated by PKA while PDE5 is also phosphorylated by PKG.

Phosphodiesterase III inhibitor class drugs taken orally and long term are associated with increased deaths in heart failure. A number of options are available to treat symptomatic chronic heart failure. These include ACE inhibitors, beta‐blockers and spironolactone, which result in an increase of life expectancy.

PDE3 inhibitors are inodilators used in heart failure. They increase contractility and dilate vessels. PDE breaks down intracellular cAMP and cyclic guanosine monophosphate (cGMP). PDE inhibitors therefore result in increased intracellular cAMP and cGMP, which cause increased intracellular calcium.